Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program StatusBusiness Wire • 09/08/25
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/07/25
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 08/07/25
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis BBusiness Wire • 08/06/25
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025Business Wire • 08/04/25
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular DystrophyBusiness Wire • 07/23/25
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards ClinicBusiness Wire • 07/16/25
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular DystrophyBusiness Wire • 06/25/25
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/15/25
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 05/15/25
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingBusiness Wire • 05/14/25
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)Business Wire • 05/07/25
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingBusiness Wire • 05/01/25
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock UpZacks Investment Research • 04/16/25
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis BBusiness Wire • 04/15/25
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/01/25
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/26/25
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business UpdateBusiness Wire • 03/26/25
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025Business Wire • 03/21/25
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025Business Wire • 03/20/25
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceBusiness Wire • 03/19/25
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis BBusiness Wire • 03/17/25
iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics MeetingBusiness Wire • 03/12/25